Lidocaine inhibits secretion of IL-8 and IL-1β and stimulates secretion of IL-1 receptor antagonist by epithelial cells

Clinical and Experimental Immunology

Volumn 127, Issue 2, 2002, Pages 226-233

  Lahav, M ^a   Levite, M ^b   Bassani, L ^c   Lang, A ^a   Fidder, H ^a   Tal, R ^a   Bar Meir, S ^a   Mayer, L ^c   Chowers, Y ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Chemokines; Cytokines; IL 1 receptor antagonist; Intestinal epithelial cells; Local anaesthetics

Indexed keywords

BUPIVACAINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 8; LIDOCAINE; MESSENGER RNA; TETRACAINE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL ISOLATION; CELL STIMULATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOREGULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION;

ADENOCARCINOMA; ANESTHETICS, LOCAL; BUPIVACAINE; COLITIS, ULCERATIVE; COLONIC NEOPLASMS; EPITHELIAL CELLS; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; INTERLEUKIN-8; INTESTINAL MUCOSA; LIDOCAINE; RNA, MESSENGER; SIALOGLYCOPROTEINS; TETRACAINE; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036126344     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2002.01747.x     Document Type: Article

References (42)

1. Interleukin 8 secretion by colonic crypt cells in vitro: Response to injury suppressed by butyrate and enhanced in inflammatory bowel disease
2. Mucosal expression of interleukin-6 and interleukin-8 messenger RNA in ulcerative colitis and in Crohn's disease
3. The central role of chemokines (chemotactic cytokines) in the immunopathogenesis of ulcerative colitis and Crohn's disease
4. Increased interleukin-8 in rectal dialysate from patients with ulcerative colitis: Evidence for a biological role for IL-8 in inflammation of the colon
5. Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease
6. Quantitative PCR analysis of TNF-alpha and IL-1 beta mRNA levels in pediatric IBD mucosal biopsies
7. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation
8. Gut lavage IgG and interleukin 1 receptor antagonist: Interleukin 1 beta ratio as markers of intestinal inflammation in children with inflammatory bowel disease
9. Differential and regulated expression of C-X-C, C-C, and C-chemokines by human colon epithelial cells
10. A distinct array of pro-inflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion
11. Differential cytokine expression by human intestinal epithelial cell lines: Regulated expression of interleukin 8
12. Entamoeba histolytica stimulates interleukin 8 from human colonic epithelial cells without parasite-enterocyte contact
13. Production of proinflammatory cytokines and inflammatory mediators in human intestinal epithelial cells after invasion by Trichinella spiralis
14. Influence of topical rectal application of drugs on dextran sulfate-induced colitis in rats
15. Beneficial effects of local or systemic lidocaine in experimental colitis
16. Ropivacaine gel in active distal ulcerative colitis and proctitis - A pharmacokinetic and exploratory clinical study
17. In vivo quantitation of local anesthetic suppression of leukocyte adherence
18. Lidocaine inhibits granulocyte adherence and prevents granulocyte delivery to inflammatory sites
19. Ropivacaine inhibits leukocyte rolling, adhesion and CD11b/CD18 expression
20. Influence of local anesthetics upon human polymorphonuclear leukocyte function in vitro. Reduction of lysosomal enzyme release and superoxide anion production
21. Cinchocaine and amethocaine inhibit activation and activity of superoxide production in human neutrophils
22. Effects of ropivacaine on eicosanoid release from human granulocytes and endothelial cells in vitro
23. Inhibitory effects of amide local anaesthetics on stimulus-induced human leukocyte metabolic activation, LTB4 release and IL-1 secretion in vitro
24. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
25. Effects of lidocaine on the function of immunocompetent cells. I. In vitro exposure of mouse spleen lymphocytes and peritoneal macrophages
26. Interleukin-13 induces IL-1 receptor antagonist gene expression and protein synthesis in peripheral blood mononuclear cells: Inhibition by an IL-4 mutant protein
27. The chemistry and pharmacology of local anaesthetics
28. Inhibition, by anaesthetic agents, of human leucocyte locomotion towards chemical attractants
29. Effects of lidocaine administration on hemodynamics and cytokine responses to endotoxemia in rabbits
30. Interferon-gamma directly affects barrier function of cultured intestinal epithelial monolayers
31. Cytokine-induced intestinal epithelial hyperpermeability: Role of nitric oxide
32. Roles of platelet-activating factor, interleukin-1beta and interleukin-6 in intestinal barrier dysfunction induced by mesenteric arterial ischemia and reperfusion
33. Biologic basis for interleukin-1 in disease
34. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice
35. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene
36. The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis
37. cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist associated with epithelium
38. Human intestinal epithelial cells secrete interleukin-1 receptor antagonist and interleukin-8 but not interleukin-1 or interleukin-6
39. Comparison of two promoters controlling expression of secreted or intracellular IL-1 receptor antagonist
40. Induction of interleukin-1 and interleukin-1 receptor antagonist
41. Induction of IL-1 receptor antagonist by interferon beta: Implication for the treatment of multiple sclerosis
42. Modulation of cytokine production by transforming growth factor-beta